ACRUX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.062 AUD | +1.64% |
|
-1.59% | +40.91% |
| 03/04 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
| 29/02 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Valuation
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 12.1 | 18.02 | - | - |
| Enterprise Value (EV) 1 | 12.1 | 15.32 | 12.82 | 2.324 |
| P/E ratio | -15.6 x | -4.69 x | 7.63 x | 1.69 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 2.77 x | 1.47 x | 0.89 x |
| EV / Revenue | - | 2.36 x | 1.04 x | 0.12 x |
| EV / EBITDA | - | -3.56 x | 6.11 x | 0.23 x |
| EV / FCF | - | -4.51 x | 4.75 x | 0.22 x |
| FCF Yield | - | -22.2% | 21.1% | 460% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 2,88,175 | 2,90,717 | - | - |
| Reference price 2 | 0.0420 | 0.0610 | 0.0610 | 0.0610 |
| Announcement Date | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 6.5 | 12.3 | 20.2 |
| EBITDA 1 | - | -4.3 | 2.1 | 10 |
| EBIT 1 | - | -3.9 | 2.4 | 10.3 |
| Operating Margin | - | -60% | 19.51% | 50.99% |
| Earnings before Tax (EBT) 1 | - | -3.8 | 2.4 | 10.4 |
| Net income 1 | -0.764 | -3.8 | 2.4 | 10.4 |
| Net margin | - | -58.46% | 19.51% | 51.49% |
| EPS 2 | -0.002700 | -0.0130 | 0.008000 | 0.0360 |
| Free Cash Flow 1 | - | -3.4 | 2.7 | 10.7 |
| FCF margin | - | -52.31% | 21.95% | 52.97% |
| FCF Conversion (EBITDA) | - | - | 128.57% | 107% |
| FCF Conversion (Net income) | - | - | 112.5% | 102.88% |
| Dividend per Share | - | - | - | - |
| Announcement Date | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 2.7 | 5.2 | 15.7 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -3.4 | 2.7 | 10.7 |
| ROE (net income / shareholders' equity) | - | - | 33% | 58.7% |
| ROA (Net income/ Total Assets) | - | - | 20% | 40.2% |
| Assets 1 | - | - | 12 | 25.87 |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share 2 | - | -0.0100 | 0.0100 | 0.0400 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.91% | 1.19Cr | |
| +21.98% | 4.39TCr | |
| +24.56% | 2.31TCr | |
| +20.07% | 1.53TCr | |
| +14.03% | 1.36TCr | |
| +46.40% | 1.2TCr | |
| -10.14% | 699.72Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +13.07% | 559.68Cr |
- Stock Market
- Equities
- ACR Stock
- Financials Acrux Limited